Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Rick Strange who wrote (870)	8/2/1999 11:05:00 PM
From: LLCF	Read Replies (1) \| Respond to of 1386

<blockbuster drug prior to structuring a marketing deal > What's the market estimates for HU-211??? DAK

To: Rick Strange who wrote (870)	8/3/1999 3:09:00 PM
From: arnie h	Read Replies (2) \| Respond to of 1386

Rick: Regardless of how good early results are for a new drug candidate, it is not easy to work out the kind of deal with big pharma many paople on this thread, and perhaps management, have been expecting (here's a lot of money and a fat royalty plus we'll do all the work). This is especially so when the small company is cash constrained and has been having problems raising funds in any straightforward way,such as has been the case with PARS. Obviously, a good deal has not yet materialized. The 2Q results are quite promising to me. The amount of loss decreased nicely along with the gain in revenues. These changes have been such that we can now hope for a breakeven at some point that is not too distant. This will be a big help in negotiating with big pharma. And searching for alternatives to big pharma can also help create additional incentive for a favorable arrangement with big pharma. The pieces are coming in place and management is showing signs of understanding what they have to do to optimize results. The next 6-12 months should be decisive for the company. Arnie